The refinancing and ATM facility underscore persistent cash burn. Watch for ATM issuances post-closing, which will dilute existing shareholders. Monitor preclinical/clinical catalysts to offset dilution; the stock may face near-term pressure as the market prices in the convertible note's discount features and potential registration of warrant shares.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 1 $0.9810entry
- T+1 · 7mo ago +1.94%α +2.28% · $1.00
- T+5 · 6mo ago +16.21%α +13.86% · $1.14
- T+20 · 6mo ago +16.21%α +10.92% · $1.14
- T+60 · 4mo ago −29.60%α −32.67% · $0.6906
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity) and issued a warrant for 2.16M shares at $1.1824, while prepaying existing convertible debentures at 103% of principal and terminating the prior ATM agreement. A new ATM facility with Yorkville Securities was also established. This financing, following a recently effective $200M S-3 shelf, signals urgent capital needs and potential dilution, weighing on the stock.
Key Financial Metrics
Key Facts
- $6M promissory note at 10% interest, issued at $5.76M (4% OID), due 12 months from closing
- Warrant to purchase 2,158,274 shares at $1.1824 per share (exercisable 6 months post-closing, 5-year term)
- Prepayment of existing Senior Secured Convertible Debentures at 103% of principal plus accrued interest
- New ATM sales agreement with Yorkville Securities under the effective S-3 shelf (up to $200M)
- S-3/A shelf registration filed April 27, 2026, declared effective April 28, 2026
- Closing expected on or around June 12, 2026, subject to conditions including repayment of existing debt
Financial Impact
$6M principal (4% OID), warrant representing ~4.1% of current shares outstanding (based on 52.6M shares outstanding estimate from market cap $53M at ~$1.01/share)
Risk Factors
- Dilution from warrant exercise and potential conversion of the note (up to 19.99% of outstanding without stockholder approval)
- Note conversion triggers after default (95% of 5-day VWAP or 92% of prior close) could lead to severe dilution if stock declines
- ATM program may be used aggressively, further pressuring share price
- Failure to meet closing conditions (e.g., debt repayment, Nasdaq listing) could disrupt financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-018464 |
| Document: 0001140361-26-018464-index-headers.html | 0001140361-26-018464 |
| Document: 0001140361-26-018464-index.html | 0001140361-26-018464 |
| Document: 0001140361-26-018464.txt | 0001140361-26-018464 |
Track record
28 reports on PDSB
7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers